Structure via PubChem · Public domain (PubChem)
(RS)-epinastine
Sign in to saveAlso known as (+-)-epinastine, 3-amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine
Epinastine (brand names Alesion, Elestat, Purivist, Relestat) is a second-generation antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis. It is produced by Allergan and marketed by Inspire in the United States. It is highly selective for the H1 receptor and does not cross the blood-brain-barrier.
Chemical data
- Formula
- C16H15N3
- Molecular weight
- 249.31 g/mol
- IUPAC name
- 2,4-diazatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine
- SMILES
- C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N
- InChIKey
- WHWZLSFABNNENI-UHFFFAOYSA-N
- XLogP
- 3.5
- Polar surface area
- 41.6 Ų
- H-bond donors
- 1
- H-bond acceptors
- 1
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2003
- Admin. routes
- topical
- Indications
- seasonal allergic rhinitis, eye allergy, allergic rhinitis, Rhinitis, Allergic, Perennial
via ChEMBL · EBI
Wikidata facts
- Subclass of
- medication
- Mass
- 249.126597
Show 6 more facts
- chemical formula
- C₁₆H₁₅N₃
- Commons category
- Epinastine
- canonical SMILES
- C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N
- World Health Organisation international non-proprietary name
- epinastine
- subject has role
- H1 antagonist
- physically interacts with
- Histamine receptor H1
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Epinastine (brand names Alesion, Elestat, Purivist, Relestat) is a second-generation antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis. It is produced by Allergan and marketed by Inspire in the United States. It is highly selective for the H1 receptor and does not cross the blood-brain-barrier.
It was patented in 1980 and came into medical use in 1994.
Excerpted from Wikipedia’s “(RS)-epinastine” article, available under the CC BY-SA 4.0 licence.